CardioVascular BioTherapeutics, Inc. is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death.

The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia).

Use of this site constitutes agreement to our Terms and Conditions and Privacy Policy.
Some content on this site requires the free Adobe Reader.
©2015 CardioVascular BioTherapeutics, Inc.